115 The LoDoCo2 trial rationale, design, and baseline characteristics 58. T. Misawa, M. Takahama, T. Kozaki, et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol, 14 (5) (2013), pp. 454-460 59. F. Martinon, V. Pétrilli, A. Mayor, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature, 440 (7081) (2006), pp. 237-241 60. J.N. Fordham, J. Kirwan, J. Cason, et al. Prolonged reduction in polymorphonuclear adhesion following oral colchicine. Ann Rheum Dis, 40 (6) (1981), pp. 605-608 61. E. Apostolidou, P. Skendros, K. Kambas, et al. Neutrophil extracellular traps regulate IL-1βmediated inflammation in familial Mediterranean fever. Ann Rheum Dis, 75 (1) (2016), pp. 269277 62. N.C. Raju, Q. Yi, M. Nidorf, et al. Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: A pilot randomized controlled trial. J Thromb Thrombolysis, 33 (1) (2012), pp. 88-94 63. ClinicalTrials.gov. COACS colchicine for acute coronary syndromes; NCT01906749. 2013. https://clinicaltrials.gov/ct2/show/NCT01906749. Accessed August 15, 2019. 64. ClinicalTrials.gov. Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke (CONVINCE). NCT02898610. https://clinicaltrials.gov/ct2/show/NCT02898610. Published 2016. Accessed August 15, 2019.
RkJQdWJsaXNoZXIy MTk4NDMw